Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.

@article{Eckstein2007PatientsWS,
  title={Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.},
  author={Anja K Eckstein and Hildegard Lax and Christian Loesch and Diana Glowacka and Marco Plicht and Klaus Mann and Joachim Esser and Nils G. Morgenthaler},
  journal={Clinical endocrinology},
  year={2007},
  volume={67 4},
  pages={
          607-12
        }
}
OBJECTIVE To evaluate the relationship between severity of Graves' ophthalmopathy (GO) and relapse/remission rate of associated thyroid disease. PATIENTS AND METHODS One hundred and fifty-eight patients with Graves' disease (GD) were seen within the first 6-12 months after the onset of GO and were followed for at least 18 months. During treatment, GO was classified as mild (n = 65) or severe course (n = 93) by severity and activity scores. All patients received standard anti-thyroid drug (ATD… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy.

  • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value

Ricardo V. García-Mayor, Paula Álvarez-Vázquez, Enrique Fluiters, Diana Valverde, Amalia Andrade
  • Endocrine
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Serum CYR61 Is Associated with Disease Activity in Graves' Orbitopathy.

  • Ocular immunology and inflammation
  • 2018
VIEW 1 EXCERPT
CITES METHODS

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence

  • International journal of endocrinology
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND